Skip to main navigation Skip to search Skip to main content

Recombinant soluble CD32 suppresses disease progression in experimental epidermolysis bullosa acquisita

Hiroaki Iwata*, Elena Pipi, Nicole Möckel, Peter Sondermann, Artem Vorobyev, Nina Van Beek, Detlef Zillikens, Ralf J. Ludwig

*Corresponding author for this work
Original languageEnglish
JournalJournal of Investigative Dermatology
Volume135
Issue number3
Pages (from-to)916-919
Number of pages4
ISSN0022-202X
DOIs
Publication statusPublished - 01.01.2015

Funding

This study was supported, in part, by grants GRK 1727/1 (Research Training Group “Modulation of Autoimmunity”), EXC 306/2 (Excellence Cluster “Inflammation at Interfaces”), both from the Deutsche Forschungsgemeinschaft, and by support from the University of Lübeck (E26-2012).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this